Precision BioSciences Inc. (NASDAQ:DTIL) saw an upside of 10.81% to $0.50 after adding $0.04on Wednesday. The 5-day average trading volume is 2,026,878 shares of the company’s common stock. It has gained $0.5100 in the past week and touched a new high 1 time within the past 5 days. An average of 1,596,620 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,164,470.
DTIL’s 1-month performance is -13.05% or -$0.1465 on its low of $0.4140 reached on 08/17/23. The company’s shares have touched a 52-week low of $0.41 and high of $1.74, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, DTIL has lost -57.63% or -$0.6955 and has reached a new high 5 times. However, the current price is down -71.02% from the 52-week high price.
Insider Transactions
DTIL stock investors last saw insider trading activity on Jun 08.Scimeca Dario (General Counsel and Secretary) most recently sold 13,361 shares at $0.75 per share on Jun 08. This transaction cost the insider $10,021. Chief Medical Officer, List Alan, sold 7,771 shares at a price of $0.79 on Apr 27. Then, on Mar 22, President and CEO Amoroso Michael sold 46,999 shares at a price of $0.82 per share. This transaction amounted to $38,539.
Valuation Metrics
DTIL stock has a beta of 1.31. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.20 while the price-to-book (PB) in the most recent quarter is 1.68.
Precision BioSciences Inc.’s quick ratio for the period ended June 29 was 2.60, with the current ratio over the same period at 2.60. The trailing 12-month EBITDA margin is -364.02%. The firm’s gross profit as reported stood at $125.46 million against revenue of $25.1 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -161.06% to -$11.89 million, while revenue of -$25.06 million was -110.77% off the previous quarter. Analysts expected DTIL to announce -$0.24 per share in earnings in its latest quarter, but it posted -$0.1, representing a 58.30% surprise. EBITDA for the quarter stood at more than -$9.7 million. DTIL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 147.66 million, with total debt at $27.99 million. Shareholders hold equity totaling $115.07 million.
Let’s look briefly at Precision BioSciences Inc. (DTIL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 43.22% to suggest the stock is trending Neutral, with historical volatility in this time period at 91.13%.
The stock’s 5-day moving average is $0.4679, reflecting a -5.81% or -$0.0305 change from its current price. DTIL is currently trading -15.47% above its 20-day SMA, -29.56% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -32.99% and SMA200 by-64.68%.
Stochastic %K and %D was 26.92% and 25.56% and the average true range (ATR) pointed at 0.0516. The RSI (14) points at 41.00%, while the 14-day stochastic is at 41.28% with the period’s ATR at 0.0513. The stock’s 9-day MACD Oscillator is pointing at -0.0291 and -0.0448 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Precision BioSciences Inc. (NASDAQ: DTIL), BMO Capital Markets launched coverage with an Outperform rating. Analysts offering their rating for DTIL stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate DTIL as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is DTIL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.00 and a high of $4.00, with their median price target at $2.25. Looking at these predictions, the average price target given by analysts is for Precision BioSciences Inc. (DTIL) stock is $2.32.
